Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
PMCID: PMC7442590
Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss
GLP-1 receptor agonists are medications (such as semaglutide, tirzepatide, and liraglutide) that mimic a natural gut hormone, helping lower blood sugar, reduce appetite, promote weight loss, and decrease inflammation. Can GLP-1 medications help with both diabetes and weight loss
Your employer or plan sponsor may not have included it as part of their benefits package
The melanocortin peptide Lys-Pro-Val has anti-inflammatory actions
US$ 23.48
US$ 25.41
US$ 21.59
